BNP Paribas Reaffirms “Outperform” Rating for Shire (SHP)
Shire (LON:SHP)‘s stock had its “outperform” rating restated by investment analysts at BNP Paribas in a report released on Tuesday. They presently have a GBX 4,700 ($63.74) price objective on the biopharmaceutical company’s stock. BNP Paribas’ price target suggests a potential upside of 36.17% from the stock’s current price.
A number of other research firms also recently commented on SHP. Goldman Sachs Group restated a “conviction-buy” rating on shares of Shire in a research report on Tuesday, October 17th. Liberum Capital cut shares of Shire to a “hold” rating and lowered their price objective for the stock from GBX 4,200 ($56.96) to GBX 4,100 ($55.60) in a research note on Wednesday, December 20th. Citigroup reaffirmed a “buy” rating and issued a GBX 5,500 ($74.59) price objective on shares of Shire in a research note on Friday, January 5th. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 5,700 ($77.30) price objective on shares of Shire in a research note on Thursday, October 5th. Finally, Morgan Stanley lowered their price objective on shares of Shire from GBX 5,800 ($78.65) to GBX 5,700 ($77.30) and set an “overweight” rating on the stock in a research note on Thursday, October 12th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of GBX 5,082.35 ($68.92).
Shire (LON:SHP) traded down GBX 48.50 ($0.66) during mid-day trading on Tuesday, hitting GBX 3,451.50 ($46.81). 3,750,000 shares of the company’s stock were exchanged, compared to its average volume of 2,410,000. Shire has a one year low of GBX 3,403.50 ($46.16) and a one year high of GBX 5,067 ($68.71). The company has a market cap of $31,400.00 and a P/E ratio of 2,696.48.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/18/bnp-paribas-reaffirms-outperform-rating-for-shire-shp.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related stocks with our FREE daily email newsletter.